DE60106002D1 - Behandlung von hematopoietischen zellen mit cxcr4 agonisten - Google Patents
Behandlung von hematopoietischen zellen mit cxcr4 agonistenInfo
- Publication number
- DE60106002D1 DE60106002D1 DE60106002T DE60106002T DE60106002D1 DE 60106002 D1 DE60106002 D1 DE 60106002D1 DE 60106002 T DE60106002 T DE 60106002T DE 60106002 T DE60106002 T DE 60106002T DE 60106002 D1 DE60106002 D1 DE 60106002D1
- Authority
- DE
- Germany
- Prior art keywords
- cells
- treatment
- cxcr4
- hematopoietic
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002305036A CA2305036A1 (en) | 2000-04-12 | 2000-04-12 | Cxcr4 agonist treatment of hematopoietc cells |
CA2305036 | 2000-04-12 | ||
US23242500P | 2000-09-14 | 2000-09-14 | |
US232425P | 2000-09-14 | ||
CA002335109A CA2335109A1 (en) | 2000-04-12 | 2001-02-23 | Cxcr4 agonist treatment of hematopoietic cells |
CA2335109 | 2001-02-23 | ||
PCT/CA2001/000540 WO2001076615A2 (en) | 2000-04-12 | 2001-04-12 | Cxcr4 agonist treatment of hematopoietic cells |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60106002D1 true DE60106002D1 (de) | 2004-11-04 |
DE60106002T2 DE60106002T2 (de) | 2006-02-02 |
Family
ID=27171219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60106002T Expired - Lifetime DE60106002T2 (de) | 2000-04-12 | 2001-04-12 | Behandlung von hämatopoetischen Zellen mit CXCR4 Agonisten |
Country Status (9)
Country | Link |
---|---|
US (1) | US20020165123A1 (de) |
EP (1) | EP1276493B1 (de) |
JP (2) | JP2003530355A (de) |
AT (1) | ATE277628T1 (de) |
AU (2) | AU5208101A (de) |
BR (1) | BR0110049A (de) |
CA (1) | CA2335109A1 (de) |
DE (1) | DE60106002T2 (de) |
WO (1) | WO2001076615A2 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2245224A1 (en) * | 1998-08-14 | 2000-02-14 | Jiang-Hong Giong | Chemokine receptor antagonists and chemotherapeutics |
CA2305787A1 (en) | 2000-05-09 | 2001-11-09 | The University Of British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
JP2002506830A (ja) * | 1998-03-13 | 2002-03-05 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 治療的ケモカイン受容体アンタゴニスト |
US7368425B2 (en) * | 2006-03-24 | 2008-05-06 | Chemokine Therapeutics Corp. | Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis |
US7378098B2 (en) | 2000-04-12 | 2008-05-27 | The University Of British Columbia | CXC chemokine receptor 4 agonist peptides |
US7091310B2 (en) * | 2002-09-13 | 2006-08-15 | Chemokine Therapeutics Corporation | Chemokine analogs for the treatment of human disease |
US20050059584A1 (en) * | 2002-08-16 | 2005-03-17 | Ahmed Merzouk | Novel chemokine mimetics synthesis and their use |
US20070116669A1 (en) * | 2002-09-13 | 2007-05-24 | Chemokine Therapeutics Corporation | Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases |
US20090118139A1 (en) * | 2000-11-07 | 2009-05-07 | Caliper Life Sciences, Inc. | Microfluidic method and system for enzyme inhibition activity screening |
US7358044B2 (en) * | 2003-04-16 | 2008-04-15 | Argyll Biotechnologies, Llc. | Prophylactic and therapeutic benefits of a new class of immune stimulating peptides |
FI20040953A0 (fi) * | 2004-07-08 | 2004-07-08 | Jari Koistinaho | Luuydinsolun stimulointimenetelmä ja luuydinsolu |
IL164942A0 (en) * | 2004-10-31 | 2005-12-18 | Yeda Res & Dev | The use of a protease or a protease inhibitor for the manufacture of medicaments |
DK1869066T3 (da) * | 2005-04-08 | 2010-03-29 | Lonza Ag | Peptidsyntese af alfa-spiraler på PEG-harpiks |
JP4839032B2 (ja) * | 2005-07-13 | 2011-12-14 | 国立大学法人 岡山大学 | ケモカイン受容体作用増強剤 |
US20090035318A1 (en) * | 2005-09-29 | 2009-02-05 | British Columbia Cancer Agency Branch | Method and composition for increasing the engraftment efficiency of stem cells |
WO2007079460A2 (en) * | 2006-01-04 | 2007-07-12 | Chemokine Therapeutics Corporation | Design of cxc chemokine analogs for the treatment of human diseases |
US7696309B2 (en) * | 2006-10-23 | 2010-04-13 | The Brigham And Women's Hospital, Inc. | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
WO2011053700A1 (en) * | 2009-10-28 | 2011-05-05 | Henry Ford Health System | Methods to mitigate injury from radiation exposure |
WO2011106234A1 (en) | 2010-02-25 | 2011-09-01 | Provasculon, Inc. | Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
US9267934B2 (en) | 2010-10-26 | 2016-02-23 | University Of South Alabama | Methods and compositions for ameliorating pancreatic cancer |
JP2014513727A (ja) | 2011-05-16 | 2014-06-05 | ジェンザイム・コーポレーション | Cxcr4拮抗薬の使用 |
WO2012170495A1 (en) | 2011-06-07 | 2012-12-13 | Provasculon, Inc. | Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2760992A (en) * | 1956-08-28 | Naphthalene | ||
US2530369A (en) * | 1948-01-29 | 1950-11-21 | Phillips Petroleum Co | Oxidation of aromatic compounds |
US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
AU6131086A (en) * | 1985-07-05 | 1987-01-30 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
JP2589094B2 (ja) * | 1986-09-13 | 1997-03-12 | 中外製薬株式会社 | 抗悪性腫瘍剤 |
US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
ATE124421T1 (de) * | 1989-09-25 | 1995-07-15 | Genetics Inst | Verfahren zur wachstumshemmung von stammzellen. |
JP3022915B2 (ja) * | 1990-07-17 | 2000-03-21 | 市郎 東 | 癌転移抑制剤 |
NZ246354A (en) * | 1991-12-23 | 1995-10-26 | British Bio Technology | Stem cell inhibiting proteins and their production and use |
CN1089344C (zh) * | 1993-03-31 | 2002-08-21 | 普罗神经细胞有限公司 | 干细胞增生的抑制剂及其应用 |
CA2117953C (en) * | 1993-10-14 | 2001-12-11 | Tasuku Honjo | Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same |
JP3532570B2 (ja) * | 1994-01-13 | 2004-05-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 哺乳類単球化学誘引物質タンパク質レセプター |
ATE216425T1 (de) * | 1994-08-13 | 2002-05-15 | Roche Diagnostics Gmbh | Verwendung von interferon-gamma zur vermeidung der proliferation und differenzierung der primitiven hämapoietischen vorläuferzellen |
US5990163A (en) * | 1995-01-13 | 1999-11-23 | The Salk Institute For Biological Studies | Selective modulation of processes mediated by retinoid X receptors, and compounds useful therefor |
US5871723A (en) * | 1995-06-06 | 1999-02-16 | The Regent Of The University Of Michigan | CXC chemokines as regulators of angiogenesis |
US6046185A (en) * | 1996-07-11 | 2000-04-04 | Inflazyme Pharmaceuticals Ltd. | 6,7-oxygenated steroids and uses related thereto |
FR2751658B1 (fr) * | 1996-07-26 | 1998-10-02 | Pasteur Institut | Utilisation d'une chemokine (sdf-1) ligand pour le recepteur de lestr/fusin/cxcr4 pour prevenir ou traiter l'infection par des virus de type vih |
AR008290A1 (es) * | 1996-08-15 | 1999-12-29 | Smithkline Beecham Corp | Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios. |
US5962462A (en) * | 1996-12-13 | 1999-10-05 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
US5919776A (en) * | 1996-12-20 | 1999-07-06 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
US6124319A (en) * | 1997-01-21 | 2000-09-26 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
US6136827A (en) * | 1997-07-25 | 2000-10-24 | Merck & Co., Inc. | Cyclic amine modulations of chemokine receptor activity |
US6166037A (en) * | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
US6013644A (en) * | 1997-12-12 | 2000-01-11 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
US6140349A (en) * | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
JP2002506830A (ja) * | 1998-03-13 | 2002-03-05 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 治療的ケモカイン受容体アンタゴニスト |
-
2001
- 2001-02-23 CA CA002335109A patent/CA2335109A1/en not_active Abandoned
- 2001-04-12 AU AU5208101A patent/AU5208101A/xx active Pending
- 2001-04-12 DE DE60106002T patent/DE60106002T2/de not_active Expired - Lifetime
- 2001-04-12 EP EP01925259A patent/EP1276493B1/de not_active Expired - Lifetime
- 2001-04-12 JP JP2001574131A patent/JP2003530355A/ja active Pending
- 2001-04-12 AU AU2001252081A patent/AU2001252081B9/en not_active Ceased
- 2001-04-12 BR BR0110049-1A patent/BR0110049A/pt not_active IP Right Cessation
- 2001-04-12 AT AT01925259T patent/ATE277628T1/de not_active IP Right Cessation
- 2001-04-12 US US09/835,107 patent/US20020165123A1/en not_active Abandoned
- 2001-04-12 WO PCT/CA2001/000540 patent/WO2001076615A2/en active IP Right Grant
-
2009
- 2009-02-04 JP JP2009023230A patent/JP2009143942A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ATE277628T1 (de) | 2004-10-15 |
US20020165123A1 (en) | 2002-11-07 |
AU2001252081B9 (en) | 2005-05-05 |
AU5208101A (en) | 2001-10-23 |
AU2001252081B2 (en) | 2004-12-23 |
WO2001076615A3 (en) | 2002-02-28 |
WO2001076615A2 (en) | 2001-10-18 |
EP1276493B1 (de) | 2004-09-29 |
EP1276493A2 (de) | 2003-01-22 |
CA2335109A1 (en) | 2001-10-12 |
JP2003530355A (ja) | 2003-10-14 |
BR0110049A (pt) | 2003-07-01 |
DE60106002T2 (de) | 2006-02-02 |
JP2009143942A (ja) | 2009-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE277628T1 (de) | Behandlung von hematopoietischen zellen mit cxcr4 agonisten | |
Kang et al. | The effect of CD34+ cell‐containing autologous platelet‐rich plasma injection on pattern hair loss: a preliminary study | |
Tsai et al. | Platelet-rich plasma releasate promotes regeneration and decreases inflammation and apoptosis of injured skeletal muscle | |
King et al. | Role of white blood cells in blood-and bone marrow-based autologous therapies | |
Mori et al. | Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia | |
LTC1131065I2 (lt) | Dialkilfumaratai, skirti autoimuninėms ligoms gydyti | |
Vanscheidt et al. | Treatment of recalcitrant venous leg ulcers with autologous keratinocytes in fibrin sealant: a multinational randomized controlled clinical trial | |
SG146666A1 (en) | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders | |
CA2567177A1 (en) | Genetically engineered cells for therapeutic applications | |
Harper et al. | Dermatological aspects of the use of Cyclosporin A for prophylaxis of graft‐versus‐host disease | |
US20190314469A1 (en) | Composition Comprising Thrombin-Treated Stem Cell-Derived Exosome For Treating Skin Wound | |
Lepistö et al. | Effects of homodimeric isoforms of platelet-derived growth factor (PDGF-AA and PDGF-BB) on wound healing in rat | |
ATE440602T1 (de) | Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion | |
Khalili et al. | Bone marrow cells are a source of undifferentiated cells to prevent Sjögren's syndrome and to preserve salivary glands function in the non-obese diabetic mice | |
IL153288A0 (en) | Use of growth hormone or a derivative thereof in the preparation of a medicament for hematopoiesis | |
ATE300310T1 (de) | Verfahren zur steigerung von hematopoietischen zellen | |
Tsutsui et al. | Treatment of cardiac disease by inhalation of atmospheric pressure plasma | |
EP1171165A4 (de) | Injektion von autologem knochenmark in den herzmuskel | |
Abraham et al. | The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation | |
Gehrig et al. | Emerging drugs for treating skeletal muscle injury and promoting muscle repair | |
EA200500757A1 (ru) | Новое применение декстрансульфата | |
WO2000061755A3 (en) | Secreted human proteins | |
Cheng et al. | Granulocyte colony-stimulating factor exacerbates cardiac fibrosis after myocardial infarction in a rat model of permanent occlusion | |
Fromes et al. | The tetrapeptide acetyl‐serine‐aspartyl‐lysine‐proline improves skin flap survival and accelerates wound healing | |
Mastim et al. | An Open-Labeled Randomized Prospective Multi-center Study to Evaluate the Efficacy and Safety of Intra-articular Injection of OSSINEXT™, an Autologous Growth Factor Concentrate (AGFC) Compared to Hyaluronic Acid (HA) in Knee Osteoarthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |